arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

CHINA PHARMA HOLDINGS, INC.

CPHI
$0.53 ▼ -0.06 (-9.46%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
66 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
29
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

CHINA PHARMA HOLDINGS, INC. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). On the positive side, Debt to Equity remains strong. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $21.5M
Dividend Yield —
Revenue Growth -7.5% ↗
Op. Margin -151.0% ↘
ROIC -3.1% ↘
FCF / Share $-0.00 ↗
Trailing P/E —
Price / Book 0.6x
FCF Yield —
Debt / Equity 0.05
info Valuation on last close. End-of-day price, Nov 5, 2026.

66-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$948.34K
↓ -7.5% —
Net Income Profit after all expenses
$-1.14M
↓ -45.5% —
Operating Margin Operating profit as % of sales
-151.0%
↓ -32.9% 3th
FCF / Share Free cash flow per share
$-0.00
↑ +62.5% —
Long-Term Debt Long-term obligations
$4.33M
↓ -13.6% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↓
13
Returns ↑
31
Financial Health ↓
49
Cash Quality
21

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 17 years · 66 quarters